Results 201 to 210 of about 26,394 (258)
Clinical tumor lysis syndrome associated with elranatamab in relapsed multiple myeloma: a case report [PDF]
Rev Fac Cien Med Univ Nac CordobaMilanesio M +3 more
europepmc +1 more source
Beyond the chimeric antigen receptor T cells and bispecific antibody duopoly: ex vivo armed T cells for solid tumors. [PDF]
Front ImmunolPark JA, Cheung NV.
europepmc +1 more source
Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Engineering bispecific antibodies
Current Opinion in Biotechnology, 1993Bispecific antibodies have immense potential as reagents and in medicine. Until recently, they were made by combining monoclonal antibodies of two different specificities in vitro, or by fusion of the corresponding hybridomas. Protein engineering now offers the chance to construct a range of small 'designer' bispecific antibodies using antibody ...
P, Holliger, G, Winter
openaire +2 more sources
Bispecific Antibodies in Lymphoma
International Reviews of Immunology, 1993info:eu-repo/semantics ...
Brissinck, J +4 more
openaire +3 more sources
Bispecific Antibodies for the Treatment of Neuroblastoma
SSRN Electronic Journal, 2022Bispecific antibodies (BsAb) are a new generation of antibody-based therapy, conveying artificial specificity to polyclonal T cells or radiohaptens. These drugs have been successfully implemented to cure hematologic malignancies and are under clinical investigation for solid tumors including HRNB.
Madelyn, Espinosa-Cotton +1 more
openaire +2 more sources
Production of Bispecific Antibodies
Current Protocols in Immunology, 1995AbstractBispecific antibodies (bsAbs) contain two different binding specificities within a single molecule and can specifically bind two different molecules together. BsAbs can be produced by chemically cross‐linking purified antibodies or Fab fragments with reducible disulfide bonds or nonreducible thioether bonds, both of which are described in this ...
David M, Segal, Bert J E G, Bast
openaire +2 more sources
A revival of bispecific antibodies
Trends in Biotechnology, 2004Bispecific antibodies usually do not occur in nature but are constructed by recombinant DNA or cell-fusion technologies. Most are designed to recruit cytotoxic effector cells of the immune system effectively against pathogenic target cells. This complex task explains why, after more than 15 years of extensive research, many different formats of ...
Peter, Kufer +2 more
openaire +2 more sources
Bispecific antibodies in oncology
Nature Reviews Drug Discovery, 2022Arman, Esfandiari +2 more
openaire +2 more sources